New York, December 13, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Aetna Inc. (NYSE: AET), Biogen Idec Inc. (NASDAQ: BIIB), Eli Lilly & Co. (NYSE: LLY), WellPoint Inc. (NYSE: WLP), and Laboratory Corp. of America Holdings (NYSE: LH). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Aetna Inc. Research Report
On December 6, 2013, Aetna Inc. (Aetna) announced that its Board of Directors has increased the Company's quarterly cash dividend by 13% to $0.225 per share on the Company's common stock. According to Aetna, the dividend will be paid on January 31, 2014, to shareholders of record at the close of the business on January 16, 2014. "The decision to increase the dividend by 13 percent demonstrates confidence in our strategy, our capital position and our cash flow," said Mark T. Bertolini, Aetna's Chairman, CEO and President. "The increased dividend is in keeping with Aetna's commitment to enhance total return for our shareholders." The Full Research Report on Aetna Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Biogen Idec Inc. Research Report
On December 4, 2013, Biogen Idec Inc. (Biogen Idec) and Swedish Orphan Biovitrum AB jointly announced the publication of detailed results from the pivotal Phase 3 study of ALPROLIX, the Companies' investigational long-lasting recombinant factor IX Fc fusion protein candidate for hemophilia B. According to the Company, the study of ALPROLIX showed that people with severe hemophilia B safely and effectively prevented or reduced bleeding episodes with prophylactic infusions every one to two weeks. Glenn Pierce, M.D., Ph.D., Senior Vice President of Global Medical Affairs and Chief Medical Officer at Biogen Idec's Hemophilia Therapeutic Area, said, "If approved, long-lasting ALPROLIX therapy will have the potential to change the way hemophilia B is managed and address a critical need for patients." The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Eli Lilly & Co. Research Report
On December 5, 2013, Eli Lilly & Co. (Eli Lilly) announced that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment. The Company informed that though the safety and tolerability of edivoxetine was consistent with previous studies, the efficacy results do not support a regulatory submission for adjunctive treatment in patients with Major Depressive Disorder (MDD). "While disappointing for people suffering from depression, their families and Lilly, negative studies are unfortunately a reality of biopharmaceutical innovation, and are particularly prevalent in the area of neuroscience given the historically high placebo response rate," said Jan Lundberg, Ph.D., Executive Vice President, Science and Technology, and President, Lilly Research Laboratories. "Lilly remains committed to our neuroscience legacy of discovering and delivering innovative medicines, as evidenced by our pipeline of nine potential new medicines and diagnostic imaging agents for neuroscience-related diseases and disorders, including Alzheimer's disease, Parkinson's disease, depression, bipolar disorder, migraine prevention and osteoarthritis pain." The Full Research Report on Eli Lilly & Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
WellPoint Inc. Research Report
On December 9, 2013, WellPoint Inc. (WellPoint) reported that its new survey, which examined the way Americans (age 45 and older) view dental coverage benefits, revealed that nine out of 10 older Americans (93%) understand the positive affect of good oral care on their overall health. According to the Company, 83%of Americans surveyed said that they have medical coverage (from either an employer or the government), although, only half as many are covered by dental insurance. "There has been a positive surge of awareness around personal health and it is assuring that baby boomers understand the link between dental care and overall health," said Dani Fjelstad, President of WellPoint's Dental business. "However, this survey uncovered a knowledge gap about dental insurance options that employers and insurers need to address." The Full Research Report on WellPoint Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Laboratory Corp. of America Holdings Research Report
On December 10, 2013, Laboratory Corporation of America Holdings (LH) announced updates from its full year 2013 guidance and along with its preliminary 2014 guidance. The Company reaffirmed its prior revenue growth guidance of approximately 3% YoY, besides updating its non-GAAP full year 2013 adjusted EPS excluding amortization guidance to between $6.90 and $7.05. The Company said that it expects to report its Q4 2013 financial results on February 7, 2014. For full-year 2014, the Company expects revenue growth of approximately 2% YoY and non-GAAP adjusted EPS of approximately $6.50. The Full Research Report on Laboratory Corp. of America Holdings - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner